Drug Profile
Research programme: anti-CD89 antibodies - Celldex Therapeutics Inc
Alternative Names: CDX-1189Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Celldex Therapeutics Inc
- Class Monoclonal antibodies
- Mechanism of Action Fc receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Kidney disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Kidney-disorders in USA (Parenteral)
- 05 Apr 2012 This programme is still active